Tadalafil vs Telmisartan
FDA Approved vs FDA Approved
synergistic Telmisartan and tadalafil have complementary blood pressure-lowering mechanisms -- ARB-mediated RAAS blockade and PDE5 inhibitor-mediated vasodilation, respectively. The combination provides enhanced BP control and may offer additive vascular and renal protective effects. Start tadalafil at a low dose (5 mg) when already on telmisartan and monitor for symptomatic hypotension.
Molecular Data
Tadalafil Telmisartan
Weight 389.40 Da 514.62 Da
Half-life ~17.5 hours ~24 hours
Type Small molecule phosphodiesterase type 5 (PDE5) inhibitor Benzimidazole derivative (C33H30N4O2)
Key Benefits
Tadalafil
01 Long-acting duration with a 36-hour therapeutic window
02 Daily low-dose option (2.5-5mg) eliminates timing constraints
03 FDA-approved for both ED and BPH/LUTS
04 Minimal food interaction compared to other PDE5 inhibitors
05 Improved endothelial function and blood flow
06 Lower incidence of visual side effects vs. sildenafil
07 Potential benefits for exercise performance via enhanced blood flow
08 Well-established long-term safety profile
Telmisartan
01 Potent 24-hour blood pressure reduction with once-daily dosing
02 Protection against AAS-induced left ventricular hypertrophy and cardiac remodeling
03 Nephroprotection through reduced intraglomerular pressure and proteinuria
04 Unique partial PPAR-gamma agonism improving insulin sensitivity and lipid metabolism
05 No negative impact on exercise performance, VO2 max, or recovery
06 Reduction of pathological vascular remodeling and arterial stiffness
07 Longest half-life of all ARBs ensuring consistent 24-hour coverage
08 Well-tolerated with a low incidence of side effects compared to ACE inhibitors (no dry cough)
Side Effects
Tadalafil
Headache (11-15% incidence, most common side effect)
Dyspepsia / indigestion (4-13%)
Back pain (3-9%, relatively unique to tadalafil among PDE5 inhibitors)
Myalgia / muscle aches (1-7%, thought to be related to PDE11 inhibition)
Nasal congestion / rhinitis (3-5%)
Flushing (1-4%)
Limb pain (1-3%)
Dizziness (1-2%)
Telmisartan
Dizziness or lightheadedness, particularly during the first few days or after dose increases
Mild hypotension, especially in volume-depleted individuals or those on concurrent antihypertensives
Upper respiratory tract infection symptoms (sinusitis, pharyngitis) - reported in clinical trials at rates similar to placebo
Back pain and myalgia (uncommon but reported)
Fatigue
Contraindications
Concurrent use of any organic nitrate medication (absolute contraindication)
Concurrent use of guanylate cyclase stimulators (e.g., riociguat)
Known hypersensitivity to tadalafil or any tablet excipient
Severe hepatic impairment (Child-Pugh Class C)
Recent stroke or myocardial infarction (within 90 days)
Unstable angina or angina during sexual intercourse
Uncontrolled hypertension (>170/100 mmHg) or hypotension (<90/50 mmHg)
NYHA Class IV heart failure
Hereditary degenerative retinal disorders (including retinitis pigmentosa)
History of NAION (relative contraindication -- increased recurrence risk)
Pregnancy (Category D - can cause fetal injury and death; discontinue immediately if pregnancy is detected)
Bilateral renal artery stenosis
Known hypersensitivity to telmisartan or any excipients
Concurrent use with aliskiren in patients with diabetes or renal impairment (eGFR <60)
Severe hepatic impairment or biliary obstruction (telmisartan is eliminated primarily via biliary excretion)
Research Evidence
Tadalafil Telmisartan
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest — 2023
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.